Is Conexeu Sciences Inc. (CNXU) a Buy, Sell, or Hold?
NASDAQ : CNXU
Conexeu Sciences Inc.
$9.59 USD
$0.71 (8.0%)
- Volume
- 50.3K
- Average Volume
- 101.44K
- Market Capitalization
- $200.63M
- P/E Ratio
- Dividend Yield
- %
- Price Target
- $20.00
- Year High
- $18.79
- Year Low
- $8.14
- Day High
- —
- Day Low
- —
- Payout Ratio
- Current Ratio
Company Overview
NASDAQ
Miles Harrison
Biotechnology
Healthcare
CNXU
4
US
USD
Liquidity Metrics
Sales & Valuation
-$
Profitability
-$
%
%
%
%
P/E Metrics
Analyst Price Target & Rating
$20.00
$20.00
$20.00
0/5
0 Analysts
-52.05%
Financial Health Scores
No financial score data available.
Key Metrics (TTM)
No key metrics data available.
Company Executives
| Name | Title |
|---|---|
| Falconne | Head of Business Development & Licensing |
| Miles D. Harrison | President, CEO & Director |
| Stephen D. Inouye | CFO, Corporate Secretary & Treasurer |
| David R. Bogart | Founder, Chief Commercial Officer & Director |
| Brian K. Pilcher | Chief Medical Officer |
| Claudia Chavez-Munoz | Founder & Chief Scientific Officer |
| Sonia Thomas | Head of Strategy & Transformation |
Poll Results
No votes yet today — be the first to share your view!
About Conexeu Sciences Inc. (NASDAQ:CNXU) Stock
Conexeu Sciences Inc. specializes in pioneering regenerative biomaterials intended for various medical fields, including wound management, dental practices, and aesthetic medicine. The enterprise began operations on November 2, 2022, co-founded by Claudia Chavez-Munoz, David R. Bogart, and Ryan Hartwell, and operates from its primary office in Reno, Nevada. ...
2026-07-15 11:01:00
/PRNewswire/ -- Equity Insider News Commentary - Every so often, a wave of demand in one corner of medicine spills over and creates an entirely new market next
2026-07-14 08:30:00
Highlights An unclaimed opportunity. Large-volume body contouring, and restoration of the breasts, hips, and buttocks is a significant injectable aesthetics category yet to be claimed.
2026-07-07 09:00:00
Study Highlights P.R.O.O.F study complete, marking an important catalyst. Conexeu has completed its P.R.O.O.F (Performance and Regeneration Outcomes of Flowable Collagen) preclinical program, which provides the evidence base behind the CXU™ platform's development direction and the Company's planned move into the medical aesthetics injectable market.
Conexeu Sciences Opens Vancouver R&D Facility to Advance Regenerative Tissue Platform
2026-06-25 08:30:00
Nasdaq-Listed Biotech Pioneer Among the First Companies to Operate at adMare's New M4 Innovation Centre Nasdaq-Listed Biotech Pioneer Among the First Companies to Operate at adMare's New M4 Innovation Centre
Conexeu Sciences: Hanging On The FDA 510(k) Pathway Submission
2026-06-24 03:55:45
Conexeu Sciences is rated Buy, leveraging a patented CXU platform targeting multi-billion-dollar regenerative medicine markets with a flagship wound care product. CNXU's Ten-Minute Tissue™ aims for FDA 510(k) clearance by Q1 2027, potentially accelerating market entry to late 2027 and minimizing investor dilution. Current valuation (~$13.20/share) exceeds risk-adjusted fair value ($10.71), but premium is justified by pipeline breadth and upside if regulatory milestones are met.
Conexeu Expands Board, Executive, and Advisory Leadership With Five Appointments Post Nasdaq Listing
2026-06-15 08:30:00
Board expansion from six to nine directors and the appointment of a Chief Commercial Officer and an advisory board member to help accelerate growth and strengthen execution Board expansion from six to nine directors and the appointment of a Chief Commercial Officer and an advisory board member to help accelerate growth and strengthen execution
2026-06-08 08:30:00
Activities are intended to support regulatory testing and the Company's planned first-quarter 2027 FDA 510(k) premarket notification submission Activities are intended to support regulatory testing and the Company's planned first-quarter 2027 FDA 510(k) premarket notification submission
Conexeu Sciences to Ring Nasdaq Bell on June 10, 2026
2026-06-03 08:30:00
RENO, Nev., June 03, 2026 (GLOBE NEWSWIRE) -- Conexeu Sciences Inc. (Nasdaq: CNXU) ("Conexeu" or the "Company"), a biotechnology company advancing tissue regeneration, will ring the Nasdaq Closing Bell on Wednesday, June 10, 2026, at the Nasdaq MarketSite in New York City in celebration of its recent public listing and the commencement of
Frequently Asked Questions
-
What is the current Conexeu Sciences Inc. (CNXU) stock price?
-
Conexeu Sciences Inc.(NASDAQ:CNXU) stock price is $9.59 in the last trading session. During the trading session, CNXU stock reached the peak price of $18.79 while $8.14 was the lowest point it dropped to. The percentage change in CNXU stock occurred in the recent session was 8.0% while the dollar amount for the price change in CNXU stock was $0.71.
-
CNXU's industry and sector of operation?
-
The NASDAQ listed CNXU is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CNXU?
-
Falconne | Head of Business Development & Licensing
Miles D. Harrison | President, CEO & Director
Stephen D. Inouye | CFO, Corporate Secretary & Treasurer
David R. Bogart | Founder, Chief Commercial Officer & Director
Brian K. Pilcher | Chief Medical Officer -
How many employees does CNXU have?
-
Number of CNXU employees currently stands at 4. CNXU operates from 50 W Liberty St, Suite 880, Reno, NV 89501, US.
-
Link for CNXU official website?
-
Official Website of CNXU is: www.conexeu.com
-
How do I contact CNXU?
-
CNXU could be contacted at phone #604-315-4722 and can also be accessed through its website. CNXU operates from 50 W Liberty St, Suite 880, Reno, NV 89501, US.
-
How many shares of CNXU are traded daily?
-
The average number of CNXU shares traded daily for last 3 months was 101.44K.
-
What is the market cap of CNXU currently?
-
The market value of CNXU currently stands at $200.63M with its latest stock price at $9.59